Compare Abeona Therapeutics Inc (ABEO) vs Salesforce Inc (CRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Salesforce Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Salesforce Inc trades at $166.49 (market cap $138.84B). The key difference: Salesforce Inc is far larger — about 371.9× Abeona Therapeutics Inc's market cap, and Salesforce Inc pays a 1.04% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CRM | |
|---|---|---|
Market Cap | $373.32M | $138.84B |
Sector | Health | Technology |
52-Week High | $7.23 | $273.65 |
52-Week Low | $4.17 | $150.12 |
Enterprise Value | $228.22M | $168.88B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Salesforce (CRM) trades at $166.00, up 0.21% on the day, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong fundamentals with a P/E of 19.64, revenue of $37.90 billion for 2025, and net income of $6.20 billion, supported by consistent earnings beats. Recent news highlights AI momentum and a significant year-to-date decline, with analyst consensus remaining strongly positive.
Outlook is favorable due to robust profitability, AI integration, and a consensus price target of $235.20, implying over 40% upside. Risks include market volatility, competitive pressures in SaaS, and macroeconomic headwinds affecting tech stocks, but strong cash flow and institutional support provide a solid foundation for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
